Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Maral Mouradian
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Procedures
Living Beings
Concepts & Ideas
Physiology
Anatomy
Sign-in to see full Profile
Network (preview)
62
Chase, Thomas
16
Fabbrini, Giovanni
14
Junn, Eunsung
12
baronti, fabio
11
Lee, Sang-Hun
9
Yajima, Shunsuke
8
Metman, Leo Verhagen
7
Jose, Pedro
7
Lee, Gwang
7
Kanazawa, Ichiro
7
okazawa, hitoshi
7
Lammers, Claas-Hinrich
6
D'Souza, Ursula
6
Blanchet, Pierre
5
Hwang, Cheol Kyu
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Maral Mouradian (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Junn Eunsung; Lee Kang-Woo; Jeong Byeong Seon; Chan Teresa W; Im Joo-Young; Mouradian M Maral
Repression of alpha-synuclein expression and toxicity by microRNA-7.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(31):13052-7.
-
2009: Lee Sang-Hyeon; Jang Min-Kyung; Kim Ok-Soo; Lee Ok-Hee; Kim Nam Young; Yoo Ki-Hwan; Lee Dong-Geun; Shong Young Hwa; Mouradian M Maral
Activation of the GDNF-inducible transcription factor (GIF) gene promoter by glucocorticoid and progesterone.
The Journal of steroid biochemistry and molecular biology 2009;115(1-2):30-5.
-
2008: Lee Sang-Hyeon; Jang Min-Kyung; Lee Ok Hee; Kim Ok Soo; Kim Yong-Man; Yajima Shunsuke; Lee Young-Choon; Mouradian M Maral
Transcriptional auto-regulation of the dopamine receptor regulating factor (DRRF) gene.
Molecular and cellular endocrinology 2008;289(1-2):23-8.
-
2008: Mochizuki Hideki; Yasuda Toru; Mouradian M Maral
Advances in gene therapy for movement disorders.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2008;5(2):260-9.
-
2008: Ryu Myung Yi; Kim Dong Wan; Arima Kunimasa; Mouradian M Maral; Kim Seung U; Lee Gwang
Localization of CKII beta subunits in Lewy bodies of Parkinson's disease.
Journal of the neurological sciences 2008;266(1-2):9-12.
-
2006: Dhib-Jalbut Suhayl; Arnold Douglas L; Cleveland Don W; Fisher Mark; Friedlander Robert M; Mouradian M Maral; Przedborski Serge; Trapp Bruce D; Wyss-Coray Tony; Yong V Wee
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.
Journal of neuroimmunology 2006;176(1-2):198-215.
-
2005: Bara-Jimenez William; Bibbiani Francesco; Morris Michael J; Dimitrova Tzvetelina; Sherzai Abdullah; Mouradian Maral M; Chase Thomas N
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2005;20(8):932-6.
-
2005: Junn Eunsung; Taniguchi Hiroyuki; Jeong Byeong Seon; Zhao Xin; Ichijo Hidenori; Mouradian M Maral
Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(27):9691-6.
-
2005: Mouradian M Maral
Should levodopa be infused into the duodenum?
Neurology 2005;64(2):182-3.
-
2004: Bara-Jimenez William; Dimitrova Tzvetelina; Sherzai Abdulah; Favit Antonella; Mouradian M M; Chase Thomas N
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2004;19(10):1183-6.
-
2004: Dhib-Jalbut Suhayl; Mouradian M Maral
Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system.
Expert opinion on biological therapy 2004;4(5):669-75.
-
2004: Makar T K; Trisler D; Eglitis M A; Mouradian M M; Dhib-Jalbut S
Brain-derived neurotrophic factor (BDNF) gene delivery into the CNS using bone marrow cells as vehicles in mice.
Neuroscience letters 2004;356(3):215-9.
-
2004: Golbe Lawrence I; Mouradian M Maral
Alpha-synuclein in Parkinson's disease: light from two new angles.
Annals of neurology 2004;55(2):153-6.
-
2004: Lee Gwang; Tanaka Mikiei; Park Kiho; Lee Sang Seop; Kim Yong Man; Junn Eunsung; Lee Sang-Hyeon; Mouradian M Maral
Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation.
The Journal of biological chemistry 2004;279(8):6834-9.
-
2004: Tanaka Mikiei; Kim Yong Man; Lee Gwang; Junn Eunsung; Iwatsubo Takeshi; Mouradian M Maral
Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.
The Journal of biological chemistry 2004;279(6):4625-31.
-
2003: Lee S S; Kim Y M; Junn E; Lee G; Park K-H; Tanaka M; Ronchetti R D; Quezado M M; Mouradian M M
Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies.
Neurobiology of aging 2003;24(5):687-96.
-
2003: Bara-Jimenez W; Sherzai A; Dimitrova T; Favit A; Bibbiani F; Gillespie M; Morris M J; Mouradian M M; Chase T N
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Neurology 2003;61(3):293-6.
-
2003: Blanchet Pierre J; Konitsiotis Spiros; Mochizuki Hideki; Pluta Ryszard; Emerich Dwaine F; Chase Thomas N; Mouradian M Maral
Complications of a trophic xenotransplant approach in parkinsonian monkeys.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(4):607-12.
-
2003: Junn Eunsung; Ronchetti Ruben D; Quezado Martha M; Kim Soo-Youl; Mouradian M Maral
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(4):2047-52.
-
2003: Lee Sang-Hyeon; Kim Yong-Man; Yajima Shunsuke; Ha Jong-Myung; Ha Bae Jin; Kim Ok Soo; Ohsawa Kanju; Mouradian M Maral
Genomic organization and promoter characterization of the murine dopamine receptor regulating factor (DRRF) gene.
Gene 2003;304():193-9.
-
2002: Junn Eunsung; Lee Sang Seop; Suhr Unsun T; Mouradian M Maral
Parkin accumulation in aggresomes due to proteasome impairment.
The Journal of biological chemistry 2002;277(49):47870-7.
-
2002: Lee Gwang; Junn Eunsung; Tanaka Mikiei; Kim Yong Man; Mouradian M Maral
Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival.
Journal of neurochemistry 2002;83(2):346-52.
-
2002: Makar Tapas Kumar; Wilt Susan; Dong Zhongyun; Fishman Paul; Mouradian M Maral; Dhib-Jalbut Suhayl
IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2002;22(7):783-91.
-
2002: Dunah Anthone W; Jeong Hyunkyung; Griffin April; Kim Yong-Man; Standaert David G; Hersch Steven M; Mouradian M Maral; Young Anne B; Tanese Naoko; Krainc Dimitri
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
Science (New York, N.Y.) 2002;296(5576):2238-43.
-
2002: Okazawa Hitoshi; Rich Tina; Chang Alex; Lin Xi; Waragai Masaaki; Kajikawa Masunori; Enokido Yasushi; Komuro Akihiko; Kato Seishi; Shibata Masao; Hatanaka Hiroshi; Mouradian M Maral; Sudol Marius; Kanazawa Ichiro
Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death.
Neuron 2002;34(5):701-13.
-
2002: Junn Eunsung; Mouradian M Maral
Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.
Neuroscience letters 2002;320(3):146-50.
-
2002: Mouradian M Maral
Recent advances in the genetics and pathogenesis of Parkinson disease.
Neurology 2002;58(2):179-85.
-
2002: D'Souza Ursula M; Lammers Claas-Hinrich; Hwang Cheol Kyu; Yajima Shunsuke; Mouradian M Maral
Developmental expression of the zinc finger transcription factor DRRF (dopamine receptor regulating factor).
Mechanisms of development 2002;110(1-2):197-201.
-
2001: Park K W; Eglitis M A; Mouradian M M
Protection of nigral neurons by GDNF-engineered marrow cell transplantation.
Neuroscience research 2001;40(4):315-23.
-
2001: Junn E; Mouradian M M
Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases.
Journal of neurochemistry 2001;78(2):374-83.
-
2001: Hwang C K; D'Souza U M; Eisch A J; Yajima S; Lammers C H; Yang Y; Lee S H; Kim Y M; Nestler E J; Mouradian M M
Dopamine receptor regulating factor, DRRF: a zinc finger transcription factor.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(13):7558-63.
-
2001: Metman L V; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian M M; Chase T N
Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Clinical neuropharmacology 2001;24(3):163-9.
-
2001: D'Souza U M; Wang W; Gao D Q; Kanda S; Lee G; Junn E; Hwang C K; Jose P A; Mouradian M M
Characterization of the 5' flanking region of the rat D(3) dopamine receptor gene.
Journal of neurochemistry 2001;76(6):1736-44.
-
2000: Yang Y; Hwang C K; Junn E; Lee G; Mouradian M M
ZIC2 and Sp3 repress Sp1-induced activation of the human D1A dopamine receptor gene.
The Journal of biological chemistry 2000;275(49):38863-9.
-
2000: Waragai M; Junn E; Kajikawa M; Takeuchi S; Kanazawa I; Shibata M; Mouradian M M; Okazawa H
PQBP-1/Npw38, a nuclear protein binding to the polyglutamine tract, interacts with U5-15kD/dim1p via the carboxyl-terminal domain.
Biochemical and biophysical research communications 2000;273(2):592-5.
-
2000: Yang Y; Hwang C K; D'Souza U M; Lee S H; Junn E; Mouradian M M
Three-amino acid extension loop homeodomain proteins Meis2 and TGIF differentially regulate transcription.
The Journal of biological chemistry 2000;275(27):20734-41.
-
2000: Kanda S; Bishop J F; Eglitis M A; Yang Y; Mouradian M M
Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.
Neuroscience 2000;97(2):279-84.
-
1999: Takeuchi S; Imafuku I; Waragai M; Roth C; Kanazawa I; Buettner R; Mouradian M M; Okazawa H
AP-2beta represses D(1A) dopamine receptor gene transcription in neuro2a cells.
Brain research. Molecular brain research 1999;74(1-2):208-16.
-
1999: Lammers C H; D'Souza U; Qin Z H; Lee S H; Yajima S; Mouradian M M
Regulation of striatal dopamine receptors by estrogen.
Synapse (New York, N.Y.) 1999;34(3):222-7.
-
1999: Bennett M C; Bishop J F; Leng Y; Chock P B; Chase T N; Mouradian M M
Degradation of alpha-synuclein by proteasome.
The Journal of biological chemistry 1999;274(48):33855-8.
-
1999: Lee S H; Mouradian M M
Up-regulation of D1A dopamine receptor gene transcription by estrogen.
Molecular and cellular endocrinology 1999;156(1-2):151-7.
-
1999: Lee S H; Yajima S; Mouradian M M
Neural cell line-specific regulatory DNA cassettes harboring the murine D1A dopamine receptor promoter.
Neuroscience research 1999;34(4):225-34.
-
1999: Blanchet P J; Fang J; Hyland K; Arnold L A; Mouradian M M; Chase T N
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study.
Neurology 1999;53(1):91-5.
-
1999: Lammers C H; D'Souza U M; Qin Z H; Lee S H; Yajima S; Mouradian M M
Regulation of striatal dopamine receptors by corticosterone: an in vivo and in vitro study.
Brain research. Molecular brain research 1999;69(2):281-5.
-
1999: Waragai M; Lammers C H; Takeuchi S; Imafuku I; Udagawa Y; Kanazawa I; Kawabata M; Mouradian M M; Okazawa H
PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival.
Human molecular genetics 1999;8(6):977-87.
-
1999: Eglitis M A; Dawson D; Park K W; Mouradian M M
Targeting of marrow-derived astrocytes to the ischemic brain.
Neuroreport 1999;10(6):1289-92.
-
1999: Eisch A J; Lammers C H; Yajima S; Mouradian M M; Nestler E J
In vivo regulation of glial cell line-derived neurotrophic factor-inducible transcription factor by kainic acid.
Neuroscience 1999;94(2):629-36.
-
1998: Imafuku I; Waragai M; Takeuchi S; Kanazawa I; Kawabata M; Mouradian M M; Okazawa H
Polar amino acid-rich sequences bind to polyglutamine tracts.
Biochemical and biophysical research communications 1998;253(1):16-20.
-
1998: Blanchet P J; Fang J; Gillespie M; Sabounjian L; Locke K W; Gammans R; Mouradian M M; Chase T N
Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.
Clinical neuropharmacology 1998;21(6):339-43.
-
1998: Yajima S; Lee S H; Minowa T; Mouradian M M
Sp family transcription factors regulate expression of rat D2 dopamine receptor gene.
DNA and cell biology 1998;17(5):471-9.
-
1998: Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian M M; Chase T N
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Neurology 1998;50(5):1323-6.
-
1997: Lee S H; Wang W; Yajima S; Jose P A; Mouradian M M
Tissue-specific promoter usage in the D1A dopamine receptor gene in brain and kidney.
DNA and cell biology 1997;16(11):1267-75.
-
1997: Yajima S; Lammers C H; Lee S H; Hara Y; Mizuno K; Mouradian M M
Cloning and characterization of murine glial cell-derived neurotrophic factor inducible transcription factor (MGIF).
The Journal of neuroscience : the official journal of the Society for Neuroscience 1997;17(22):8657-66.
-
1997: Bishop J F; Joshi G; Mueller G P; Mouradian M M
Localization of putative calcium-responsive regions in the rat BDNF gene.
Brain research. Molecular brain research 1997;50(1-2):154-64.
-
1997: Metman L V; van den Munckhof P; Klaassen A A; Blanchet P; Mouradian M M; Chase T N
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
Neurology 1997;49(3):711-3.
-
1997: Blanchet P J; Papa S M; Metman L V; Mouradian M M; Chase T N
Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
Neuroscience and biobehavioral reviews 1997;21(4):447-53.
-
1997: Mouradian M M; Chase T N
Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
Experimental neurology 1997;144(1):51-7.
-
1997: Verhagen Metman L; Locatelli E R; Bravi D; Mouradian M M; Chase T N
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
Neurology 1997;48(2):369-72.
-
1997: Chernak J M; Hoffman P W; Minowa T; Mouradian M M; Roth G S
Interaction of nuclear factors from young and old rat brain regions with regulatory sequences of the D2 dopamine receptor gene promoter.
Brain research. Molecular brain research 1997;44(1):113-24.
-
1996: Okazawa H; Imafuku I; Minowa M T; Kanazawa I; Hamada H; Mouradian M M
Regulation of striatal D1A dopamine receptor gene transcription by Brn-4.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(21):11933-8.
-
1996: Lee S H; Minowa M T; Mouradian M M
Two distinct promoters drive transcription of the human D1A dopamine receptor gene.
The Journal of biological chemistry 1996;271(41):25292-9.
-
1996: Blanchet P J; Metman L V; Mouradian M M; Chase T N
Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1996;11(5):580-1.
-
1996: Minowa M T; Lee S H; Mouradian M M
Autoregulation of the human D1A dopamine receptor gene by cAMP.
DNA and cell biology 1996;15(9):759-67.
-
1996: Wang W; Hahn K H; Bishop J F; Gao D Q; Jose P A; Mouradian M M
Up-regulation of D3 dopamine receptor mRNA by neuroleptics.
Synapse (New York, N.Y.) 1996;23(3):232-5.
-
1996: Metman L V; Blanchet P J; de Jong D; Mouradian M M; Chase T N
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1996;11(3):257-60.
-
1996: Imafuku I; Kamei M; Kanazawa I; Mouradian M M; Okazawa H
POU transcription factors differentially regulate the D1A dopamine receptor gene in cultured cells.
Biochemical and biophysical research communications 1996;222(3):736-41.
-
1996: Chase T N; Engber T M; Mouradian M M
Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
Advances in neurology 1996;69():497-501.
-
1994: Bishop J F; Mueller G P; Mouradian M M
Alternate 5' exons in the rat brain-derived neurotrophic factor gene: differential patterns of expression across brain regions.
Brain research. Molecular brain research 1994;26(1-2):225-32.
-
1994: Metman L V; Sethy V H; Roberts J R; Bravi D; Hoff J I; Mouradian M M; Chase T N
Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1994;9(5):577-81.
-
1994: Litvan I; Blesa R; Clark K; Nichelli P; Atack J R; Mouradian M M; Grafman J; Chase T N
Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
Annals of neurology 1994;36(1):55-61.
-
1994: Bravi D; Mouradian M M; Roberts J W; Davis T L; Sohn Y H; Chase T N
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Annals of neurology 1994;36(1):27-31.
-
1994: Metman L V; Hoff J; Mouradian M M; Chase T N
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Movement disorders : official journal of the Movement Disorder Society 1994;9(4):463-5.
-
1994: Chase T N; Engber T M; Mouradian M M
Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
Neurology 1994;44(7 Suppl 6):S15-8.
-
1994: Blin J; Piercey M F; Giuffra M E; Mouradian M M; Chase T N
Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography.
Journal of the neurological sciences 1994;123(1-2):44-51.
-
1994: Gao D Q; Canessa L M; Mouradian M M; Jose P A
Expression of the D2 subfamily of dopamine receptor genes in kidney.
The American journal of physiology 1994;266(4 Pt 2):F646-50.
-
1994: Sohn Y H; Metman L V; Bravi D; Linfante I; Aotsuka A; Mouradian M M; Chase T N
Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
Neurology 1994;44(4):755-7.
-
1994: Minowa T; Minowa M T; Mouradian M M
Negative modulator of the rat D2 dopamine receptor gene.
The Journal of biological chemistry 1994;269(15):11656-62.
-
1994: Blin J; Ray C A; Piercey M F; Bartko J J; Mouradian M M; Chase T N
Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography.
Brain research 1994;635(1-2):196-202.
-
1994: Randolph C; Roberts J W; Tierney M C; Bravi D; Mouradian M M; Chase T N
D-cycloserine treatment of Alzheimer disease.
Alzheimer disease and associated disorders 1994;8(3):198-205.
-
1993: Chase T N; Mouradian M M; Engber T M
Motor response complications and the function of striatal efferent systems.
Neurology 1993;43(12 Suppl 6):S23-7.
-
1993: Roberts J W; Cora-Locatelli G; Bravi D; Amantea M A; Mouradian M M; Chase T N
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Neurology 1993;43(12):2685-8.
-
1993: Minowa M T; Minowa T; Mouradian M M
Activator region analysis of the human D1A dopamine receptor gene.
The Journal of biological chemistry 1993;268(31):23544-51.
-
1993: Bishop J F; Mouradian M M
Characterization of a corticotropin releasing hormone responsive region in the murine proopiomelanocortin gene.
Molecular and cellular endocrinology 1993;97(1-2):165-71.
-
1993: Bravi D; Mouradian M M; Roberts J W; Davis T L; Chase T N
End-of-dose dystonia in Parkinson's disease.
Neurology 1993;43(10):2130-1.
-
1993: Giuffra M; Mouradian M M; Davis T L; Ownby J; Chase T N
Dynorphin agonist therapy of Parkinson's disease.
Clinical neuropharmacology 1993;16(5):444-7.
-
1993: Felder R A; Kinoshita S; Ohbu K; Mouradian M M; Sibley D R; Monsma F J; Minowa T; Minowa M T; Canessa L M; Jose P A
Organ specificity of the dopamine1 receptor/adenylyl cyclase coupling defect in spontaneously hypertensive rats.
The American journal of physiology 1993;264(4 Pt 2):R726-32.
-
1993: Bravi D; Davis T L; Mouradian M M; Chase T N
Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Movement disorders : official journal of the Movement Disorder Society 1993;8(2):195-7.
-
1993: Yamaguchi I; Jose P A; Mouradian M M; Canessa L M; Monsma F J; Sibley D R; Takeyasu K; Felder R A
Expression of dopamine D1A receptor gene in proximal tubule of rat kidneys.
The American journal of physiology 1993;264(2 Pt 2):F280-5.
-
1993: Horiuchi A; Takeyasu K; Mouradian M M; Jose P A; Felder R A
D1A dopamine receptor stimulation inhibits Na+/K(+)-ATPase activity through protein kinase A.
Molecular pharmacology 1993;43(2):281-5.
-
1993: Mouradian M M; Minowa M T; Minowa T
Promoter structure of the human gene coding for the D1A dopamine receptor.
Advances in neurology 1993;60():343-5.
-
1993: Chase T N; Engber T M; Mouradian M M
Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
Advances in neurology 1993;60():181-5.
-
1993: Giuffra M E; Sethy V H; Davis T L; Mouradian M M; Chase T N
Milacemide therapy for Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1993;8(1):47-50.
-
1992: Baronti F; Mouradian M M; Davis T L; Giuffra M; Brughitta G; Conant K E; Chase T N
Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
Annals of neurology 1992;32(6):776-81.
-
1992: Minowa T; Minowa M T; Mouradian M M
Analysis of the promoter region of the rat D2 dopamine receptor gene.
Biochemistry 1992;31(36):8389-96.
-
1992: Baronti F; Mouradian M M; Conant K E; Giuffra M; Brughitta G; Chase T N
Partial dopamine agonist therapy of levodopa-induced dyskinesias.
Neurology 1992;42(6):1241-3.
-
1992: Minowa M T; Minowa T; Monsma F J; Sibley D R; Mouradian M M
Characterization of the 5' flanking region of the human D1A dopamine receptor gene.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(7):3045-9.
-
1992: Giuffra M E; Mouradian M M; Chase T N
Glutamatergic therapy of Huntington's chorea.
Clinical neuropharmacology 1992;15(2):148-51.
-
1992: Baronti F; Davis T L; Boldry R C; Mouradian M M; Chase T N
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.
Neurology 1992;42(3 Pt 1):541-4.
-
1992: Heuser I J; Baronti F; Marin C A; Ma N; Merriam G R; Chase T N; Mouradian M M
Growth hormone secretion in Alzheimer's disease: 24-hour profile of basal levels and response to stimulation and suppression studies.
Neurobiology of aging 1992;13(2):255-60.
-
1991: Baronti F; Ruggieri S; Mouradian M M; Bonamartini A; Bocciarelli P; De Pandis M F; Chase T N; Agnoli A
[Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease]
Rivista di neurologia 1991;61(6):210-4.
-
1991: Heuser I J; Chase T N; Mouradian M M
The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease.
Biological psychiatry 1991;30(9):943-52.
-
1991: Mouradian M M; Blin J; Giuffra M; Heuser I J; Baronti F; Ownby J; Chase T N
Somatostatin replacement therapy for Alzheimer dementia.
Annals of neurology 1991;30(4):610-3.
-
1991: Baronti F; Conant K E; Giuffra M; Davis T L; Brughitta G; Iadarola M J; Berrettini W H; Chase T N; Mouradian M M
Opioid peptides in Parkinson's disease: effects of dopamine repletion.
Brain research 1991;560(1-2):92-6.
-
1991: Davis T L; Brughitta G; Baronti F; Mouradian M M
Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics.
Neurology 1991;41(5):630-3.
-
1991: Mouradian M M; Heuser I J; Baronti F; Giuffra M; Conant K; Davis T L; Chase T N
Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1991;54(5):401-5.
-
1990: Mouradian M M; Heuser I J; Baronti F; Chase T N
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
Annals of neurology 1990;27(1):18-23.
-
1990: Chase T N; Fabbrini G; Juncos J L; Mouradian M M
Motor response complications with chronic levodopa therapy.
Advances in neurology 1990;53():377-81.
-
1989: Chase T N; Baronti F; Fabbrini G; Heuser I J; Juncos J L; Mouradian M M
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Neurology 1989;39(11 Suppl 2):7-10; discussion 19.
-
1989: Litvan I; Gomez C; Atack J R; Gillespie M; Kask A M; Mouradian M M; Chase T N
Physostigmine treatment of progressive supranuclear palsy.
Annals of neurology 1989;26(3):404-7.
-
1989: Mouradian M M; Heuser I J; Baronti F; Fabbrini G; Juncos J L; Chase T N
Pathogenesis of dyskinesias in Parkinson's disease.
Annals of neurology 1989;25(5):523-6.
-
1989: Braun A; Mouradian M M; Mohr E; Fabbrini G; Chase T N
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
Journal of neurology, neurosurgery, and psychiatry 1989;52(5):631-5.
-
1988: Chase T N; Juncos J L; Fabbrini G; Mouradian M M
Motor response complications in advanced Parkinson's disease.
Functional neurology 1988;3(4):429-36.
-
1988: Mouradian M M; Juncos J L; Fabbrini G; Schlegel J; Bartko J J; Chase T N
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
Annals of neurology 1988;24(3):372-8.
-
1988: Fabbrini G; Mouradian M M; Juncos J L; Schlegel J; Mohr E; Chase T N
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
Annals of neurology 1988;24(3):366-71.
-
1988: Mouradian M M; Chase T N
Central mechanisms and levodopa response fluctuations in Parkinson's disease.
Clinical neuropharmacology 1988;11(4):378-85.
-
1988: Mouradian M M; Mohr E; Williams J A; Chase T N
No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
Neurology 1988;38(4):606-8.
-
1988: Fabbrini G; Braun A; Mouradian M M; Tamminga C A; Chase T N
Dopamine D-1 receptor agonist stimulation of prolactin secretion in man.
Journal of neural transmission 1988;71(3):159-63.
-
1987: Juncos J L; Fabbrini G; Mouradian M M; Serrati C; Chase T N
Dietary influences on the antiparkinsonian response to levodopa.
Archives of neurology 1987;44(10):1003-5.
-
1987: Mouradian M M; Juncos J L; Fabbrini G; Chase T N
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
Annals of neurology 1987;22(4):475-9.
-
1987: Mouradian M M; Juncos J L; Serrati C; Fabbrini G; Palmeri S; Chase T N
Exercise and the antiparkinsonian response to levodopa.
Clinical neuropharmacology 1987;10(4):351-5.
-
1987: Juncos J L; Mouradian M M; Fabbrini G; Serrati C; Chase T N
Levodopa methyl ester treatment of Parkinson's disease.
Neurology 1987;37(7):1242-5.
-
1987: Fabbrini G; Juncos J L; Mouradian M M; Serrati C; Chase T N
3-O-methyldopa and motor fluctuations in Parkinson's disease.
Neurology 1987;37(5):856-9.
-
1987: Fabbrini G; Juncos J; Mouradian M M; Serrati C; Chase T N
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
Annals of neurology 1987;21(4):370-6.
-
1987: Juncos J L; Fabbrini G; Mouradian M M; Serrati C; Kask A M; Chase T N
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1987;50(2):194-8.
-
1987: Braun A; Fabbrini G; Mouradian M M; Serrati C; Barone P; Chase T N
Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.
Journal of neural transmission 1987;68(1-2):41-50.
Sign-in to see more
